EI

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

EI

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

EI

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

EI

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

EI

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

Search

Pharming Group NV

Geschlossen

1.27 4.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.212

Max

1.293

Schlüsselkennzahlen

By Trading Economics

Einkommen

19M

4.7M

Verkäufe

14M

93M

EPS

0.006

Gewinnspanne

5.035

Angestellte

404

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+97.24% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

233M

850M

Vorheriger Eröffnungskurs

-3.52

Vorheriger Schlusskurs

1.27

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Sept. 2025, 23:37 UTC

Heiße Aktien

Stocks to Watch: Oracle, Wearable Devices, GameStop

9. Sept. 2025, 20:41 UTC

Ergebnisse

Oracle's Backlog Surges With Major Customer Deals in 1Q

9. Sept. 2025, 20:30 UTC

Ergebnisse

GameStop 2Q Sales, Profit Rise

9. Sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9. Sept. 2025, 21:35 UTC

Ergebnisse

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 21:32 UTC

Ergebnisse

Oracle's Backlog Swells With Big Customer Deals -- Update

9. Sept. 2025, 21:02 UTC

Akquisitionen, Fusionen, Übernahmen

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Sept. 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9. Sept. 2025, 20:26 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:23 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:12 UTC

Ergebnisse

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Operating Income Was $4.3 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9. Sept. 2025, 20:07 UTC

Ergebnisse

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Software Revenue $5.72B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Synopsys 3Q Adj EPS $3.39 >SNPS

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Cloud Revenue $7.19B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Rev $14.93B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q EPS $1.01 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Synopsys 3Q EPS $1.50 >SNPS

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Services Revenue $1.35B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Adj EPS $1.47 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Hardware Revenue $670M >ORCL

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Kursziel

By TipRanks

97.24% Vorteil

12-Monats-Prognose

Durchschnitt 2.446 EUR  97.24%

Hoch 2.45 EUR

Tief 2.45 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pharming Group NV – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat